全文获取类型
收费全文 | 154022篇 |
免费 | 14206篇 |
国内免费 | 8640篇 |
专业分类
耳鼻咽喉 | 1484篇 |
儿科学 | 2234篇 |
妇产科学 | 3152篇 |
基础医学 | 16016篇 |
口腔科学 | 3048篇 |
临床医学 | 19180篇 |
内科学 | 23394篇 |
皮肤病学 | 1856篇 |
神经病学 | 7883篇 |
特种医学 | 5216篇 |
外国民族医学 | 47篇 |
外科学 | 15930篇 |
综合类 | 24864篇 |
现状与发展 | 28篇 |
一般理论 | 19篇 |
预防医学 | 11517篇 |
眼科学 | 3998篇 |
药学 | 16397篇 |
134篇 | |
中国医学 | 8187篇 |
肿瘤学 | 12284篇 |
出版年
2024年 | 449篇 |
2023年 | 2128篇 |
2022年 | 5142篇 |
2021年 | 6708篇 |
2020年 | 5067篇 |
2019年 | 4508篇 |
2018年 | 4809篇 |
2017年 | 4539篇 |
2016年 | 4056篇 |
2015年 | 6372篇 |
2014年 | 8254篇 |
2013年 | 8417篇 |
2012年 | 12156篇 |
2011年 | 13064篇 |
2010年 | 9148篇 |
2009年 | 7502篇 |
2008年 | 9285篇 |
2007年 | 9233篇 |
2006年 | 8771篇 |
2005年 | 7912篇 |
2004年 | 5795篇 |
2003年 | 5470篇 |
2002年 | 4517篇 |
2001年 | 3751篇 |
2000年 | 3441篇 |
1999年 | 3079篇 |
1998年 | 1586篇 |
1997年 | 1442篇 |
1996年 | 1140篇 |
1995年 | 1084篇 |
1994年 | 1003篇 |
1993年 | 577篇 |
1992年 | 946篇 |
1991年 | 866篇 |
1990年 | 720篇 |
1989年 | 618篇 |
1988年 | 564篇 |
1987年 | 473篇 |
1986年 | 384篇 |
1985年 | 302篇 |
1984年 | 201篇 |
1983年 | 170篇 |
1982年 | 96篇 |
1981年 | 97篇 |
1979年 | 140篇 |
1978年 | 111篇 |
1977年 | 83篇 |
1974年 | 94篇 |
1973年 | 72篇 |
1972年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
44.
Xia Li Wang Junni Xie Xishao Xiang Shilong Zhang Xiaohui Chen Jianghua Han Fei 《中华肾脏病杂志》2020,36(7):497-502
Objective To observe the clinical characteristics and prognosis of patients with rapidly progressive glomerulonephritis (RPGN) caused by lupus nephritis, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, or primary glomerulonephritis who were treated with peritoneal dialysis (PD) and then withdrew PD because of renal recovery. Methods Data of the above patients were retrospectively analyzed. The patients were diagnosed as RPGN and received PD therapy in Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University from February 2009 to August 2018. The patients were divided into early withdrawal group (PD time≤183 days, n=24) and late withdrawal group (PD time>183 day, n=24). The differences of clinical characteristics between the two groups were compared. The cumulative incidence of adverse events in both groups was analyzed using Kaplan-Meier curves. Cox proportional hazards model was used to analyze the risk factors influencing the prognosis of patients. Results Forty-eight RPGN patients were included. The median time of maintaining PD was 178(76, 378) days. Compared with the late withdrawal group, the patients in early withdrawal group had lower levels of urine volume, serum albumin and parathyroid hormone, and lower rates of gross hematuria and hypertension at the beginning of PD, and received higher rates of methylprednisolone impulse, combined immunosuppressive agents, and hemodialysis or continuous renal replacement therapy (all P<0.05). At the time of PD withdrawal, the levels of serum creatinine, serum calcium, serum albumin and parathyroid hormone in the early withdrawal group were significantly lower than those in the late withdrawal group (all P<0.05). The Kaplan-Meier curves showed that there was no significant difference in the cumulative survival of patients in both groups (log-rank test χ2=3.485, P=0.062). Cox regression analysis revealed serum creatinine≥209 μmol/L at the time of PD withdrawal was an independent risk factor for poor prognosis (HR=5.253,95%CI 1.757-15.702, P=0.003). Conclusions PD can be used for RPGN patients caused by lupus nephritis, ANCA-associated vasculitis and primary nephritis. Serum creatinine≥209 μmol/L at the time of PD withdrawal is an independent risk factor for poor prognosis. 相似文献
45.
目的:探讨美托洛尔(β1受体阻滞剂)用于老年COPD合并冠心病史治疗的临床疗效。方法:选取2018年6月—2019年6月在我院接受治疗的60岁以上(包括60岁)COPD合并冠心病史老年患者,分为对照组与观察组。对照组给予接受布地奈德福莫特罗粉吸入剂治疗,观察组在使用布地奈德福莫特罗粉吸入剂治疗的基础上口服琥珀酸美托洛尔缓释片治疗,观察对比两组治疗效果。结果:观察组临床治疗效果优于对照组,观察组住院时长以及并发症的发生率低于对照组(P<0.05),差异具有统计学意义。结论:老年COPD合并冠心病史接受美托洛尔治疗,可有效缩短住院时长、用药效果明显、有效提升用药安全性,值得临床推广。 相似文献
46.
47.
Multidisciplinary predialysis education and team care (MDC) may slow the decline in renal function in patients with chronic kidney disease (CKD). However, associations between unexpected return during MDC and progression of renal dysfunction have not been characterized in patients with CKD. Our study aimed to determine the association between exacerbation of renal dysfunction and the frequency of unexpected return during follow-up.A total of 437 patients with CKD receiving multidisciplinary care between January 2009 and June 2013 at the Shin-Kong Wu Ho-Su Memorial Hospital were included in this retrospective observational cohort study, and multiple imputations were performed for missing data. The predictor was the frequency of unexpected return for follow-up during the first year after entering MDC. Main outcome was monthly declines in estimated glomerular filtration rates (eGFR). Moreover, the demographic data, comorbidities, history of medication, and routine laboratory data for patients with CKD were collected.Among all patients, 59.7% were male, the mean age at initiation of MDC was 69.4 ± 13.2 years, and the duration of follow-up was 21.4 ± 3.3 months. The subjects were divided into 2 groups according to frequencies of follow-up (≤4 and > 4 visits) during the 1st year of MDC. The patients with CKD were regularly followed up every 3 months as a part of MDC in our hospital, and patients who returned for more than 4 follow-up visits were included in the unexpected return group. In crude regression analyses, unexpected return was significantly associated with higher monthly declines of eGFR (β = 0.092, 95% confidence interval, 0.014–0.170). This association remained after adjustments for multiple variables, and subgroup analyses of unexpected return showed that male gender, older age, CKD stage 1 to 3, hypertension, history of coronary artery disease, and use of renin–angiotensin system blockade were significantly associated with declines in renal function.In conclusion, unexpected return for follow-up during the 1st year of MDC was significantly associated with the deterioration of renal function. 相似文献
48.
目的:评定LC-MS/MS法测定人血浆中布康唑浓度的不确定度。方法:分析测定过程中不确定度的来源,包括对照品的称量、仪器误差、标准溶液的配制、含药血浆样品的配制、血浆样品的处理、标准曲线的拟合、基质效应、重复性等,评定各来源分量的不确定度,计算合成不确定度和扩展不确定度。结果:人血浆中低(60.0 pg·mL-1)、中(600.0 pg·mL-1)、高(6 400.0 pg·mL-1)浓度布康唑的扩展不确定度分别为5.62,63.90,626.26 pg·mL-1(k=2,P=95%)。结论:LC-MS/MS法测定人血浆中布康唑浓度的不确定度主要由基质效应、血浆样品的处理(提取回收率),仪器误差、重复性(精密度)引入。 相似文献
49.
50.